异基因造血干细胞移植后高危或复发急性白血病患者供者来源TAA-T细胞治疗结局
本研究评估了靶向WT1、PRAME和survivin三种肿瘤相关抗原的供者来源TAA-T细胞疗法,用于异基因造血干细胞移植后复发或高复发风险的急性白血病患者。23例受者输注后无细胞因子释放综合征或神经毒性,仅1例发生3级移植物抗宿主病。复发患者TAA-T后1年总生存率36%,高危抢先治疗患者中位生存未达到。
要点
- 23例移植后急性白血病患者输注供者来源TAA-T细胞,剂量0.5至4×10^7/m2。
- 无患者发生细胞因子释放综合征或神经毒性,仅1例发生3级移植物抗宿主病。
- 复发患者TAA-T后1年总生存率36%,1年无白血病生存率27.3%。
核心结论
- TAA-T细胞安全且耐受良好,在高危和复发患者中观察到持续缓解。
- 经T细胞受体V-β测序检测,过继转移的TAA-T在输注后至少持续存在1年。
研究设计与样本
- 1期研究,纳入23例异基因造血干细胞移植后复发/难治(n=11)和/或高危(n=12)急性白血病患者,其中急性髓系白血病20例、急性淋巴细胞白血病3例。
- 淋巴细胞取自造血干细胞移植供者,制备为靶向WT1、PRAME和survivin三种肿瘤相关抗原的TAA-T细胞。
- 患者接受的TAA-T输注剂量为0.5至4×10^7/m2。
- 该试验在clinicaltrials.gov注册,注册号为NCT02203903。
主要发现
- 无患者发生细胞因子释放综合征或神经毒性,仅1例患者发生3级移植物抗宿主病。
- 移植后复发并接受桥接治疗的患者中,多数(n=9/11)在接收TAA-T前达到完全血液学缓解。
- 复发患者TAA-T后1年总生存率为36%,1年无白血病生存率为27.3%。
- 预后最差的患者(移植后<6个月复发)复发后1年总生存率为42.8%(n=7)。
- 接受移植后抢先TAA-T的高危患者(n=12)中位生存未达到。
局限性
- 原文为1期研究,允许同时使用抗白血病治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration of a novel T-cell therapeutic targeting 3 tumor-associated antigens (TAA-T) in patients with acute leukemia who relapsed or were at high risk of relapse after allogeneic BMT. Lymphocytes obtained from the BMT donor were manufactured to target TAAs WT1, PRAME, and survivin, which are over-expressed and immunogenic in most hematologic malignancies. Patients received TAA-T infusions at doses of 0.5 to 4 × 107/m2. Twenty-three BMT recipients with relapsed/refractory (n = 11) and/or high-risk (n = 12) acute myeloid leukemia (n = 20) and acute lymphoblastic leukemia (n = 3) were infused posttransplant. No patient developed cytokine-release syndrome or neurotoxicity, and only 1 patient developed grade 3 graft-versus-host disease. Of the patients who relapsed post-BMT and received bridging therapy, the majority (n = 9/11) achieved complete hematologic remission before receiving TAA-T. Relapsed patients exhibited a 1-year OS of 36% and 1-year leukemia-free survival of 27.3% post-TAA-T. The poorest prognosis patients (relapsed <6 months after transplant) exhibited a 1-year OS of 42.8% postrelapse (n = 7). Median survival was not reached for high-risk patients who received preemptive TAA-T posttransplant (n = 12). Although as a phase 1 study, concomitant antileukemic therapy was allowed, TAA-T were safe and well tolerated, and sustained remissions in high-risk and relapsed patients were observed. Moreover, adoptively transferred TAA-T detected by T-cell receptor V-β sequencing persisted up to at least 1 year postinfusion. This trial was registered at clinicaltrials.gov as #NCT02203903.
引用
- Kinoshita H, Cooke KR, Grant M, et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 2022. PMID: 35244681. doi:10.1182/bloodadvances.2021006831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。